tiprankstipranks
Trending News
More News >
Clearside Biomedical (CLSD)
NASDAQ:CLSD
US Market
Advertisement

Clearside Biomedical (CLSD) Stock Forecast & Price Target

Compare
1,078 Followers
See the Price Targets and Ratings of:

CLSD Financial Forecast

CLSD Earnings Forecast

Next quarter’s earnings estimate for CLSD is -$0.75 with a range of -$1.20 to -$0.45. The previous quarter’s EPS was -$1.50. CLSD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CLSD has Performed in-line its overall industry.
Next quarter’s earnings estimate for CLSD is -$0.75 with a range of -$1.20 to -$0.45. The previous quarter’s EPS was -$1.50. CLSD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CLSD has Performed in-line its overall industry.

CLSD Sales Forecast

Next quarter’s sales forecast for CLSD is $97.00K with a range of $0.00 to $290.00K. The previous quarter’s sales results were $492.00K. CLSD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CLSD has Performed in-line its overall industry.
Next quarter’s sales forecast for CLSD is $97.00K with a range of $0.00 to $290.00K. The previous quarter’s sales results were $492.00K. CLSD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CLSD has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading
Hold
Reiterated
08/11/25
Hold Rating on Clearside Biomedical Amid Financial Uncertainty and Strategic Exploration
Needham
$45
Hold
1122.83%
Upside
Reiterated
08/11/25
Needham Reaffirms Their Hold Rating on Clearside Biomedical (CLSD)We maintain our Hold rating.
Stifel Nicolaus Analyst forecast on CLSD
Stifel Nicolaus
Stifel Nicolaus
$120$30
Hold
715.22%
Upside
Downgraded
07/18/25
Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
H.C. Wainwright Analyst forecast on CLSD
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/18/25
Clearside Biomedical downgraded to Neutral from Buy at H.C. WainwrightClearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright
Citizens JMP Analyst forecast on CLSD
Citizens JMP
Citizens JMP
Hold
Downgraded
07/17/25
Citizens JMP downgrades Clearside Biomedical (CLSD) to a Hold
Chardan Capital Analyst forecast on CLSD
Chardan Capital
Chardan Capital
Hold
Downgraded
07/17/25
Clearside Biomedical (CLSD) was downgraded to a Hold Rating at Chardan Capital
Oppenheimer
$75
Buy
1938.04%
Upside
Reiterated
11/13/24
Oppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading
Hold
Reiterated
08/11/25
Hold Rating on Clearside Biomedical Amid Financial Uncertainty and Strategic Exploration
Needham
$45
Hold
1122.83%
Upside
Reiterated
08/11/25
Needham Reaffirms Their Hold Rating on Clearside Biomedical (CLSD)We maintain our Hold rating.
Stifel Nicolaus Analyst forecast on CLSD
Stifel Nicolaus
Stifel Nicolaus
$120$30
Hold
715.22%
Upside
Downgraded
07/18/25
Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
H.C. Wainwright Analyst forecast on CLSD
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/18/25
Clearside Biomedical downgraded to Neutral from Buy at H.C. WainwrightClearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright
Citizens JMP Analyst forecast on CLSD
Citizens JMP
Citizens JMP
Hold
Downgraded
07/17/25
Citizens JMP downgrades Clearside Biomedical (CLSD) to a Hold
Chardan Capital Analyst forecast on CLSD
Chardan Capital
Chardan Capital
Hold
Downgraded
07/17/25
Clearside Biomedical (CLSD) was downgraded to a Hold Rating at Chardan Capital
Oppenheimer
$75
Buy
1938.04%
Upside
Reiterated
11/13/24
Oppenheimer Keeps Their Buy Rating on Clearside Biomedical (CLSD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Clearside Biomedical

1 Month
xxx
Success Rate
5/15 ratings generated profit
33%
Average Return
-2.57%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -2.57% per trade.
3 Months
xxx
Success Rate
4/15 ratings generated profit
27%
Average Return
-6.70%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 26.67% of your transactions generating a profit, with an average return of -6.70% per trade.
1 Year
Success Rate
4/15 ratings generated profit
27%
Average Return
-22.79%
reiterated a buy rating 12 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -22.79% per trade.
2 Years
xxx
Success Rate
1/15 ratings generated profit
7%
Average Return
-43.63%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 6.67% of your transactions generating a profit, with an average return of -43.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CLSD Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
8
6
0
0
0
Buy
0
0
0
0
0
Hold
5
15
14
13
4
Sell
3
2
0
0
0
Strong Sell
2
4
5
4
2
total
18
27
19
17
6
In the current month, CLSD has received 0 Buy Ratings, 4 Hold Ratings, and 2 Sell Ratings. CLSD average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

CLSD Stock Forecast FAQ

What is CLSD’s average 12-month price target, according to analysts?
Currently, no data Available
What is CLSD’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CLSD, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is CLSD a Buy, Sell or Hold?
      Clearside Biomedical has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
        What is Clearside Biomedical’s price target?
        Currently, no data Available
        What do analysts say about Clearside Biomedical?
        Clearside Biomedical’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
          How can I buy shares of CLSD?
          Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis